OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

Shares of Ovid Therapeutics (OVID) plunged 76% on Monday after it announced that treatment with soticlestat, its Takeda (TAK) -partnered investigational epilepsy drug, failed to meet the primary endpoint of two pivotal late-stage studies. Image Source: Zacks Investment Research Ovid's partner Takeda evaluated soticlestat for treating two rare and severe forms of epilepsy, namely Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), in the late-stage SKYLINE and SKYWAY studies, respectively. While the SKYL ...